Capsule formulations
AssigneeChemoCentryx, Inc.
InventorsManhoman Reddy LELETI, Jay P. POWERS
Life of this patent
Estimating the term…
Abstract
The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.
Claims30
A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt
- and a vehicle comprising
- at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 and selected from the group consisting of a polyoxyethylene derivative of a fatty acid containing from about 8 to 22 carbon atoms, a polyoxyethylene hydrogenated castor oil or a polyoxyethylene castor oil, and
- at least one water-soluble solubilizer having a melting point at or above 37° C. and selected from the group consisting of PEG-1000, PEG-1500, PEG-1540, PEG-2000, PEG-3000, PEG-3350, PEG-4000, PEG-6000, PEG-8000, PEG-10000, PEG-20000, poloxamer 188, poloxamer 237, poloxamer 338 and poloxamer 407.
Dependencies are inferred from the claim text.